Study of Hematological and Biochemical Markers Including Hepcidin in Chronic Kidney Disease Non-Dialysis-Dependent Patients
International Journal of Current Pharmaceutical Review and Research · 30.06.2026 · 18 (06)
DOI: 10.25258/ijcpr.18.6.136 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.06.2026. Verfasst von Harpreet Kaur Matharu und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Chronic Kidney Disease (CKD) is a progressive systemic disorder associated with widespread hematological and biochemical derangements. Anemia is an early, debilitating complication predominantly driven by reduced erythropoietin (EPO) synthesis, chronic inflammation, and defective iron homeostatic mechanisms. Serum hepcidin has recently emerged as a key regulatory hormone implicated in functional iron deficiency during CKD progression.
Aim
A Study aim is to analyze the clinical significance of specific hematopoietic markers (Erythropoietin and Hepcidin), liver aminotransferases (SGPT/ALT and SGOT/AST), and renal function markers (Serum Creatinine) in non-dialysis dependent (NDD) CKD patients, evaluating their cross-correlations across progressive disease stages. Methodology: A cross-sectional observational clinical study evaluated 150 non-dialysis dependent CKD patients aged over 18 years. Laboratory assessments quantified serum erythropoietin, hepcidin (via ELISA), and serum glutamate pyruvate transaminase (SGPT/ALT), and serum glutamic oxaloacetic transaminase (SGOT/AST), and serum creatinine levels across stages 3, 4, and 5. Statistical cross-correlations were calculated to establish the systemic pathophysiological relationships.
Results
Serum creatinine and serum hepcidin levels increased progressively and significantly with advancing stages of renal dysfunction. In contrast, serum erythropoietin levels exhibited a continuous decline as kidney disease progressed. Changes in liver aminotransferases (SGOT and SGPT) were relatively minor and did not show a direct association with serum hepcidin levels. However, SGOT levels demonstrated a noticeable reduction from baseline with increasing severity of renal impairment.
Conclusion
As chronic kidney disease (CKD) progresses to more advanced stages, serum creatinine and hepcidin levels rise concurrently. The negative relationship between declining erythropoietin production and increasing hepcidin concentrations underscores the complex mechanisms contributing to anemia in non-dialysisdependent CKD (NDD-CKD). Regular assessment of these biomarkers can provide valuable clinical insight for the early management of systemic complications prior to the initiation of dialysis.
Zitieren
APA
Matharu, H. K., Mandia, P., Verma, A., & Devanda, R. (2026). Study of Hematological and Biochemical Markers Including Hepcidin in Chronic Kidney Disease Non-Dialysis-Dependent Patients. International Journal of Current Pharmaceutical Review and Research, 18(06). https://doi.org/10.25258/ijcpr.18.6.136
Vancouver
Matharu HK, Mandia P, Verma A, Devanda R. Study of Hematological and Biochemical Markers Including Hepcidin in Chronic Kidney Disease Non-Dialysis-Dependent Patients. International Journal of Current Pharmaceutical Review and Research. 2026;18(06). doi:10.25258/ijcpr.18.6.136
BibTeX
@article{Matharu2026,
author = {Matharu, Harpreet Kaur and Mandia, Priyanka and Verma, A.K. and Devanda, Rashmi},
title = {Study of Hematological and Biochemical Markers Including Hepcidin in Chronic Kidney Disease Non-Dialysis-Dependent Patients},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {06},
doi = {10.25258/ijcpr.18.6.136}
}
EUVIMED